fosun pharma issued its 2014 social responsibility report with an emphasis on communication with stakeholders
this report is written in accordance to the “the gri sustainability reporting guidelines” (version g4) by global reporting initiative (gri), and also in the light of the core program of gri4. the report also complies with appendix 27 of the listing rules (“appendix 27”) issued by the stock exchange of hong kong limited. meantime, we entrusted the report to the independent and non-rival sgs-cstc standards technical services co., ltd (“sgs”), who shall provide an independent verification service. the on-spot examination covers fosun pharma as well as yaopharma and carelife, two member companies of fosun pharma, which fully demonstrates the openness, transparency and authenticity of the report.
this report contains six sections: “strategy and management”, “finance”, “quality of product and service”, “environmental, health and safety”, “staff” and “society”. compared with the 2013 report, an emphasis is placed on the company’s strategic moves concerning the communication with stakeholders, and there will be a more detailed and systematic information disclosure. the company has formulated policies attending to the concerns of stakeholders, which involves stakeholders, such as shareholders, partners, staff, clients and customers and the public, into the process through different mechanisms, and offers them a full perspective to the social responsibility practices of the company. what the report presents covers five major business sectors of the company: pharmaceutical manufacturing, distribution and retail, healthcare services, medical devices and diagnostic products, fully revealing the practices and achievements of the company’s sustainable development.
meanwhile, according to the requirements of appendix 27, and taking into consideration an integrated and balanced way of reporting, we disclose more information concerning quality of product and service, environmental health and safety, staff, etc. and in terms of visual expression, this report presents richer and more concise graphic statistics, highlighting the key data in the report with less text description, so it appears to be more intuitional.
chen qiyu, chairman of fosun pharma, commented that a more harmonious ecosphere stems from companies’ self-discipline. the company shall give impetus to the establishment of higher and stricter standards of sustainable development, and take initiatives to purify the market environment of pharmaceuticals industry, thus contributing to a healthier and more sustainable development of the industry. yao fang, president of fosun pharma, said that the company shall maintain a continuous, honest and open information communication with the society, and apply the ideals of sustainable development and decision-making under its guidance of the company into its business operations, to requite the stakeholders to the maximum extent.
in the examination statement, sgs claimed that this year’s report is more systematic and complete in terms of its substantiality and the stakeholders’ participation and responsiveness. following the compilation standards specified in g4, the report defines relevant substantial issues and makes the sustainable development strategy and social responsibility system more complete, thus setting an example for member companies, cooperating enterprises and even the pharmaceuticals industry. the company offers more opportunities for an effective and comprehensive communication of stakeholders, and has long been engaged in the construction of a more harmonious industry ecosphere, and the establishment of a union of excellent enterprises within this industry. through effective communication and exchange, the report gives response to the concerns of the stakeholders, and it also offers a detailed disclosure of how they are responded.
fosun pharma issued its first corporate social responsibility report in 2009 and since then, the report has been issued at the same time with its a-share annual report for the sixth consecutive years. in 2014, the company’s 2013 corporate social responsibility report was rated “annual aa ” by the rankins csr ratings (ranked the third in 665 a-share listed companies altogether), ranked no. 1 in pharmaceuticals industry.
the company has long been adhering to the principle of sustainable development, remaining committed to promote the public welfare and construct a more harmonious industry ecosphere. at present, the company has built a complete public welfare system - “future star” public welfare program. by investing in education, supporting scientific researches, engaging in the community healthcare, treating diseased orphans, alleviating poverty by donations, and providing disaster assistances, we undertake our social responsibilities and do our part in benefiting the society.